NCT04148937 - A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

May 12, 2021

Study Completion Date

June 20, 2022

Conditions

Advanced Cancer

Interventions

DRUG

LY3475070

Administered orally

DRUG

Pembrolizumab

Administered IV

Trial Locations (12)

3000

Peter MacCallum Cancer Centre, Melbourne

32746

Florida Cancer Specialists ORLANDO/DDU, Lake Mary

37203

Sarah Cannon Research Institute SCRI, Nashville

44195

Cleveland Clinic Foundation, Cleveland

49546

START Midwest, Grand Rapids

63110

Washington University Medical School, St Louis

77030

University of Texas MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute at HealthOne, Denver

CB2 0QQ

Addenbrookes Hospital, Cambridge

G12 0YN

Beatson West of Scotland Cancer Center, Glasgow

M20 4 BX

Christie NHS Foundation Trust, Manchester

SM2 5PT

Royal Marsden NHS Trust, Sutton

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY